Peking University First Hospital: Carcinoma, Renal Cell trials
The registry lists 12 Carcinoma, Renal Cell studies with Peking University First Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.
Early Phase 1 1No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- 18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal TumorsRecruitingNCT07875959Not applicable
- 68Ga- and 18F-CAIX PET Imaging StudyNot yet recruitingNCT07875946Early Phase 1
- 18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsRecruitingNCT07557225Not applicable
- CAIX PET/ CT Guided Radiation Therapy in CcRCC.RecruitingNCT07540260Not applicable
- Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CTRecruitingNCT07166445
- SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal CancerRecruitingNCT06583070
- 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell CarcinomaRecruitingNCT06519760Not applicable
- Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell CarcinomaRecruitingNCT06391879
- Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI TherapyRecruitingNCT06317298Not applicable
- Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer PatientsCompletedNCT06531629
- Optimization of Management for Sporadic Bilateral Renal Cell CarcinomaCompletedNCT06369519
- Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell CarcinomaStatus unknownNCT04609293